PT  - JOURNAL ARTICLE
AU  - James Nagarajah
AU  - Marcel Janssen
AU  - Philipp Hetkamp
AU  - Walter Jentzen
TI  - Iodine Symporter Targeting with <sup>124</sup>I/<sup>131</sup>I Theranostics
AID  - 10.2967/jnumed.116.186866
DP  - 2017 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 34S--38S
VI  - 58
IP  - Supplement 2
4099  - http://jnm.snmjournals.org/content/58/Supplement_2/34S.short
4100  - http://jnm.snmjournals.org/content/58/Supplement_2/34S.full
SO  - J Nucl Med2017 Sep 01; 58
AB  - Theranostics, a modern approach combining therapeutics and diagnostics, is among the most promising concepts in nuclear medicine for optimizing and individualizing treatments for many cancer entities. Theranostics has been used in clinical routines in nuclear medicine for more than 60 y—as 131I for diagnostic and therapeutic purposes in thyroid diseases. In this minireview, we provide a survey of the use of 2 different radioiodine isotopes for targeting the sodium–iodine symporter in thyroid cancer and nonthyroidal neoplasms as well as a brief summary of theranostics for neuroendocrine neoplasms and metastatic castration-refractory prostate cancer. In particular, we discuss the role of 124I-based dosimetry in targeting of the sodium–iodine symporter and describe the clinical application of 124I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation treatment with the mitogen-activated extracellular signal–related kinase kinase inhibitor trametinib.